I agree, most currently invested now and on this board (without actual medical backgrounds) view Kevetrin as a wonder drug and expect vastly different outcomes for the trial, whether justified or not, from other trials.  I, too, have been under the impression we see some efficacy about cohort 5 and MTD somewhere at 8-9, thus giving patients quite some time to start seeing  tumor reduction.

That seems to be an erroneous view according to seel, whose opinion I value more than any other, but are there others that share this same idea as me or did I pull another expectation out of thin air and unbounded optimism?

I will continue on my pollyanna path for phase 1 results and hope Kevetrin surprises way to the upside as you predicted in your side bet.  Deep down I will realize results may not be as overwhelming as I expect and that would not be all bad from the view of the medical/scientific community.